Jan 25, 2021 7:30 am EST Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Dec 21, 2020 12:20 pm EST Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
Oct 27, 2020 6:30 am EDT Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
Oct 6, 2020 4:01 pm EDT Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
Aug 17, 2020 7:00 am EDT Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
Aug 10, 2020 4:01 pm EDT Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
Jul 10, 2020 7:30 am EDT Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
